ReviewExpert reviews in molecular medicine2026
The Tumor-Platelet-Immune Interface: Driving Metastasis, Pre-Metastatic Niche Formation and Therapeutic Vulnerabilities.
Review in Expert reviews in molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic dissemination remains the leading cause of cancer-related mortality, driven not only by tumor-intrinsic factors but also by dynamic interactions within the tumor microenvironment (TME). Platelets and leukocytes orchestrate a systemic pro-metastatic network by shielding circulating tumor cells (CTCs), inducing neutrophil extracellular trap (NET) formation, and remodeling the extracellular matrix to prime pre-metastatic niches. This platelet-leukocyte crosstalk simultaneously promotes immune evasion, thromboinflammation, and metastatic seeding, creating a multi-cellular, temporally coordinated program that conventional anti-platelet and anti-inflammatory therapies inadequately target. Here, we propose a next-generation, multi-stimuli-responsive nanoparticle platform designed to disrupt these interconnected metastatic circuits. Engineered to respond to acidic pH in primary tumors and matrix metalloproteinases in pre-metastatic niches, these nanoparticles enable spatiotemporally controlled release of cytotoxic agents, anti-platelet drugs, and immune checkpoint inhibitors. Surface functionalization with anti-P-selectin further enhances specificity to tumor vasculature and facilitates platelet ‘hitchhiking’ for targeting CTCs. By simultaneously neutralizing platelet-leukocyte interactions, inhibiting NET-mediated scaffolds, and restoring anti-tumor immunity, this integrated strategy addresses multiple pro-metastatic mechanisms in a coordinated fashion. This work provides a conceptual and translational framework for precision anti-metastatic therapeutics, transforming the paradigm from single-pathway interventions to network-targeted strategies that disrupt tumor progression, CTC survival and metastatic niche formation. Our approach represents a critical step toward actionable, multi-modal interventions capable of preventing metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.